Figure 1
![Figure 1. Kaplan-Meier analysis of OS and PFS after 90Y-ibritumomab separated by group and stratum. (A) With a median follow-up time of 21.7 months, median survival was 21.4 months (95% confidence interval [CI] = 9.3, NC) for stratum AI, 22.4 months (95% CI = 17.6, NC) for stratum AII, and 4.6 months (95% CI = 3.0, NC) for group B. The follow-up period continued until 1 year after the last patient received 90Y-ibritumomab. (B) The median PFS was 5.9 months for stratum AI (95% CI = 3.3-15.0) and 3.5 months for stratum AII (95% CI = 2.8-10.2). In group B, the median PFS was 1.6 months (95% CI = 1.4-1.7). NC indicates not calculated.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/110/1/10.1182_blood-2007-01-068056/2/zh80130703460001.jpeg?Expires=1722775908&Signature=H97UaUuJyuuJgEmpTmmfeyEhi4jdXwMQ7~kLRwyVeahJt5qFTW45AQNyD2skwclGt2R6GaaN-lPyY-fjHu8FbqwC3LK1chezY6ksaQKQUCdVY2mIftU7iZL5BesNKOrL4AKbA4dwQfPvoHGLf6SbAfLQ19yXZ4efaTATSBniVqeLbxyAeIli-dM4Cw5nFYhd9YEYoFMeNvY7s7yO7MTvVHrFHz7nJ07Wy-8wEphJADVI33RO4S0PYd9ST0NYiqw~2Ygk5cA7TaV9Iitb31-Xzj8jwwUVrBkOFJ~6AZDiDFwlNRgTTAMhDYN2aWLN3C~BA25adaNc53Xjv-9vUusHew__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Kaplan-Meier analysis of OS and PFS after 90Y-ibritumomab separated by group and stratum. (A) With a median follow-up time of 21.7 months, median survival was 21.4 months (95% confidence interval [CI] = 9.3, NC) for stratum AI, 22.4 months (95% CI = 17.6, NC) for stratum AII, and 4.6 months (95% CI = 3.0, NC) for group B. The follow-up period continued until 1 year after the last patient received 90Y-ibritumomab. (B) The median PFS was 5.9 months for stratum AI (95% CI = 3.3-15.0) and 3.5 months for stratum AII (95% CI = 2.8-10.2). In group B, the median PFS was 1.6 months (95% CI = 1.4-1.7). NC indicates not calculated.
